What is NanoSyrinx?
NanoSyrinx is an award-winning biotechnology company specializing in the creation of protein nanosyringes designed for the precise intracellular delivery of biologic drugs. Leveraging advanced synthetic biology techniques, the company aims to overcome the persistent challenges associated with delivering therapeutics, particularly antibodies and peptides, to their intracellular targets. Their proprietary platform technology is engineered to unlock cellular interiors, facilitating targeted delivery of therapeutic proteins and addressing the long-standing issue of undruggable intracellular targets. With a strong leadership team and a focus on advancing biotherapeutics, NanoSyrinx is poised to make significant contributions to the field.
How much funding has NanoSyrinx raised?
NanoSyrinx has raised a total of $21.5M across 2 funding rounds:
Angel/Seed
$8.5M
Other Financing Round
$13M
Angel/Seed (2021): $8.5M with participation from Merck Ventures
Other Financing Round (2024): $13M led by Octopus Ventures and BGF
Key Investors in NanoSyrinx
Octopus Ventures
Octopus Ventures is a venture capital firm that backs companies aiming to change the world, investing across software, climate, health, consumer, and financial technology with a focus on mission-driven enterprises.
BGF
BGF is a UK-based investor focused on supporting small and mid-sized businesses, providing capital and guidance to companies across various stages of growth and diverse economic sectors.
Merck Ventures
M Ventures is the strategic venture capital arm of Merck, investing globally in innovative technologies and products that have the potential to significantly impact its core business areas, with a strong focus on early-stage investments.
What's next for NanoSyrinx?
The recent major strategic investment signifies a pivotal moment for NanoSyrinx, likely enabling the company to accelerate its research and development pipeline, scale its manufacturing capabilities, and advance its protein nanosyringe technology towards clinical trials. This substantial capital infusion, coupled with the company's existing enterprise-level funding, positions NanoSyrinx for significant growth and market penetration. The focus will likely be on validating the efficacy and safety of their delivery system, forging strategic partnerships within the pharmaceutical industry, and ultimately bringing their innovative therapeutic solutions to patients.
See full NanoSyrinx company page
